USA - NASDAQ:PLRZ - IL0011814113 - Common Stock
The current stock price of PLRZ is 1.03 USD. In the past month the price decreased by -5.5%. In the past year, price decreased by -99.65%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.76 | 388.38B | ||
| AMGN | AMGEN INC | 13.31 | 156.26B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.43 | 68.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 343.06 | 58.46B | ||
| ARGX | ARGENX SE - ADR | 61.3 | 50.01B | ||
| INSM | INSMED INC | N/A | 41.43B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.24B | ||
| NTRA | NATERA INC | N/A | 26.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.84B | ||
| BIIB | BIOGEN INC | 8.87 | 21.77B | 
 Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. The firm is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The firm is focused not only on the development of intranasal products, but also on commercialization. The firm cooperates with medical specialists and researchers..
POLYRIZON LTD
HaTidhar St. 5
Ra'anana IL
Employees: 1
Phone: 97293740120
Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. The firm is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The firm is focused not only on the development of intranasal products, but also on commercialization. The firm cooperates with medical specialists and researchers..
The current stock price of PLRZ is 1.03 USD.
PLRZ does not pay a dividend.
PLRZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
ChartMill assigns a fundamental rating of 3 / 10 to PLRZ. PLRZ has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months PLRZ reported a non-GAAP Earnings per Share(EPS) of -134.31. The EPS decreased by -74.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.51% | ||
| ROE | -9.7% | ||
| Debt/Equity | 0 |